TGNA:FRA
Transgene SA
€ 0.67
arrow_downward
-0.59%(-0.0040) Siku 1
14 Okt, 22:00:00 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya TGNA...
Fungua
€ 0.67
Juu
€ 0.67
Chini
€ 0.67
Mtaji wa soko
193.04M
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 1.48
Chini kwa wiki 52
€ 0.60
EPS
-€ 0.17
Idadi ya wafanyakazi
152
Fungua
€ 0.67
Juu
€ 0.67
Chini
€ 0.67
Mtaji wa soko
193.04M
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 1.48
Chini kwa wiki 52
€ 0.60
EPS
-€ 0.17
Idadi ya wafanyakazi
152
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Stocktwits
·
saa 1 iliyopita
S&P 500, Nasdaq See Worst Day In Over Two Months As Chipmaker Rout Deepens, CPI Data Comes In Hot — AAPL, SPCX, DRAM, SOXX In Focus
MarketBeat
·
dakika 18 zilizopita
CoreWeave (NASDAQ:CRWV) CRO Jonathan Jones Sells 15,811 Shares of Stock
The Motley Fool
·
dakika 5 zilizopita
The S&P 500 Has Risen 30.6% in the First 20 Months of Trump's Second Term, Just Ahead of the 28.5% Gain Over the Same Stretch of His First Term. Here's Why That Comparison Matters for Investors Heading Into the Midterms.
Bloomberg.com
·
saa 4 zilizopita
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
Wasifu
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Kuhusu Transgene SA